The Comorbidity Fallacy: How the DSM, Psychiatric Practice, and Pharmaceutical Incentives Have Systematically Misclassified, Overmedicated, and Harmed Millions of Anxiety Sufferers

1. The Comorbidity Assumption

In contemporary psychiatric practice, it is standard clinical procedure to assign multiple diagnoses to patients presenting with anxiety disorders. A patient presenting with persistent worry, sleep disturbance, fatigue, concentration difficulties, and low mood will typically receive diagnoses of Generalised Anxiety Disorder and Major Depressive Disorder. A patient with panic attacks, agoraphobic avoidance, and intrusive thoughts about harm will typically receive diagnoses of Panic Disorder, Agoraphobia, and OCD. The assignment of multiple diagnoses to a single presentation has become so normalised in psychiatric practice that its conceptual foundation is rarely examined.

That conceptual foundation — the comorbidity framework — assumes that the co-occurring conditions are independently caused, maintain independent pathophysiological processes, and require independent treatments. This assumption drives the prescription of multiple psychoactive agents to the same patient: an SSRI for the GAD, a second SSRI or antidepressant for the MDD, a benzodiazepine for acute anxiety episodes, a sleep aid for the insomnia. The resulting polypharmacy regimen is itself associated with significant adverse outcomes — drug-drug interactions, additive cognitive impairment, and the escalating difficulty of disentangling drug effects from disorder effects.

This paper argues that the comorbidity assumption is incorrect in the majority of anxiety disorder presentations. The co-occurring symptoms that receive multiple diagnostic labels are not independent disorders. They are consequences — predictable, neurobiologically explicable consequences — of a single pathophysiological process: the chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis and its cascading effects on neurological, endocrine, and behavioural functioning.

2. The Psychophysiology of Apparent Comorbidity

Chronic amygdala hyperactivation — the primary neurobiological event in anxiety disorders — drives sustained HPA axis activation. Prolonged HPA activation produces elevated cortisol, which in turn produces a well-documented array of physiological and neurological consequences: sleep architecture disruption, attentional dysregulation, hippocampal volume reduction, disruption of dopaminergic reward processing, and progressive immune dysregulation.

Each of these consequences maps directly onto diagnostic criteria for conditions that are classified as comorbid with anxiety disorders. Sleep architecture disruption produces the insomnia, early waking, and fatigue that are diagnostic criteria for Major Depressive Disorder. Attentional dysregulation produces the concentration difficulties that appear in both MDD and ADHD diagnostic criteria. Dopaminergic reward processing disruption produces the anhedonia and motivational deficit that are core MDD symptoms. Hippocampal volume reduction impairs contextual memory and emotional regulation in ways that contribute to the presentation of PTSD-like symptoms.

The diagnostic error is visible: the DSM assigns independent diagnostic labels to a set of symptoms that are, neurobiologically, consequences of a single upstream process. The patient does not have GAD and MDD. The patient has a chronically activated HPA axis, and the consequences of that activation include the symptoms that psychiatry's symptom-cluster-based diagnostic system assigns to two separate conditions.

The clinical test for this hypothesis is straightforward: if the apparent comorbidities are consequences of the primary anxiety disorder rather than independent conditions, they should resolve when the primary disorder is resolved — without specific treatment for the comorbid conditions. This is precisely what the TRT outcome data demonstrate. In the Institute's naturalistic dataset (CLI-WP-003), patients presenting with both GAD-7-defined anxiety and PHQ-9-defined depression at baseline show PHQ-9 normalisation rates of 87.3% at 6-month follow-up — despite receiving no depression-specific treatment. The resolution of the anxiety disorder resolves the apparent comorbidity.

3. Institutional Origins of the Comorbidity Fallacy

The DSM's symptom-cluster approach to psychiatric diagnosis was a deliberate methodological choice made in DSM-III (1980) in response to the perceived unreliability of earlier, theory-laden diagnostic systems. By defining disorders as clusters of observable symptoms rather than by aetiological mechanism, DSM-III produced a more reliable (inter-rater consistent) diagnostic system. It did not produce a more valid (mechanistically accurate) one.

The consequence of symptom-cluster diagnosis without mechanistic foundation is exactly what has transpired: a proliferation of diagnostic categories, each corresponding to a different cluster of symptoms that may share a single underlying mechanism, and a corresponding proliferation of pharmacological treatments — each targeting the symptom cluster of one diagnostic category — applied simultaneously to patients whose presentations span multiple categories.

The pharmaceutical industry's role in the perpetuation of the comorbidity framework requires explicit acknowledgement. The commercial value of comorbidity diagnosis is substantial: a patient with two diagnoses receives two prescriptions; a patient with three diagnoses receives three. The DSM diagnostic process — however academically motivated its individual contributors — operates within a financial ecosystem in which the multiplication of diagnoses and prescriptions is commercially rewarded. The evidence that pharmaceutical companies have systematically influenced DSM diagnostic criteria through the funding of key opinion leaders, the sponsorship of diagnostic conferences, and the construction of clinical trial designs that favour their proprietary agents is well-documented (Cosgrove et al., 2006; Angell, 2004).

This paper does not claim that all DSM diagnostic categories are commercially motivated confections. It claims that the application of comorbidity frameworks to anxiety disorder presentations is specifically harmful, and that the institutional and financial incentives that perpetuate this framework are identifiable and have been identified.

4. The Harm of Misclassification

The clinical consequences of the comorbidity fallacy for anxiety disorder patients are measurable and serious. First, polypharmacy: the prescription of multiple psychoactive agents — SSRIs, SNRIs, benzodiazepines, antipsychotics, sleep medications — to patients who present with symptoms that are consequences of a single anxiety disorder. The adverse effects of this polypharmacy include cognitive impairment, metabolic dysregulation, endocrine disruption, and the well-documented difficulty of disentangling drug effects from disorder effects during any subsequent attempt at pharmacological review.

Second, chronicity: patients who receive treatment directed at the symptom clusters of apparent comorbidities — but not at the primary amygdala hyperactivation that drives them — do not recover. Their symptoms are managed, modulated, and suppressed, but the underlying pathophysiological process persists. The natural clinical consequence is chronic, treatment-maintained disorder — exactly the long-term outcome profile that is well-documented in the published literature on anxiety and depression.

Third, iatrogenic harm: some of the apparent comorbidities that develop in anxiety disorder patients are themselves consequences of pharmacological treatment rather than the underlying disorder. Benzodiazepine dependence produces anxiety symptoms that are clinically indistinguishable from the primary anxiety disorder. SSRI-associated emotional blunting is misidentified as anhedonia, which is then treated with an additional antidepressant. The iatrogenic production of comorbid symptoms through pharmacological treatment is a documented clinical phenomenon that the comorbidity framework systematically fails to identify.

5. Resolution: The Case for Primary Disorder Identification

The clinical resolution of the comorbidity fallacy is the identification and treatment of the primary disorder — the amygdala hyperactivation and HPA dysregulation that drives the presenting symptom clusters — rather than the simultaneous treatment of multiple apparent comorbidities.

In practice, this means applying a mechanism-first assessment framework before assigning multiple diagnoses. The clinical question is not 'which DSM categories does this presentation fit?' but 'what primary neurobiological process is producing this presentation?' In anxiety disorder presentations with apparent comorbid depression, the first clinical question is whether the depressive symptoms predate the anxiety disorder. If they do not — if the sleep disturbance, fatigue, anhedonia, and low mood emerged in the context of established anxiety disorder — they are consequences of HPA dysregulation, not independent depression, and they should be treated as such.

TRT's outcome profile provides the empirical support for this approach. The systematic resolution of apparent comorbid depression in patients treated for the primary anxiety disorder — without depression-specific treatment — is the clinical demonstration that the comorbidity, in these cases, was always a consequence of the primary condition rather than an independent one.

6. Conclusion

The comorbidity fallacy has contributed to three decades of clinical harm. It has produced unnecessary polypharmacy, chronic iatrogenic disorder, and the systematic failure to identify a single primary condition whose resolution would restore health — rather than multiple conditions whose symptoms can be managed indefinitely.

This paper is not a call for the abandonment of psychiatric diagnosis. It is a call for mechanistic rigour in the application of diagnostic categories to anxiety disorder presentations — rigour that the DSM's symptom-cluster framework does not provide and has never claimed to provide. The neurobiological evidence for a single primary process underlying the most common apparent comorbidities in anxiety disorder presentations is substantial. The clinical and ethical case for acting on that evidence is urgent.

The Institute invites engagement from clinicians, researchers, and policymakers who wish to develop the evidence base for primary disorder identification as an alternative to comorbidity proliferation in the clinical management of anxiety.

References

Angell, M. (2004). The Truth About the Drug Companies. Random House.

Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 75(3), 154–160.

Kessler, R. C., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 593–602.

McEwen, B. S. (2008). Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. European Journal of Pharmacology, 583(2–3), 174–185.

Tsigos, C., & Chrousos, G. P. (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 865–871.

Zimmerman, M., & Chelminski, I. (2003). Generalized anxiety disorder in patients with major depression: Is DSM-IV's hierarchy correct? American Journal of Psychiatry, 160(3), 504–512.